Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.46 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14117419 | 0.86 | KMT2A (0.58) | KMT2AMEN1BCL2L3MBTL1HPGD | |
| SCHEMBL10268514 | 0.86 | KMT2A (0.50) | KMT2AMEN1L3MBTL1HPGDTDP1 | |
| SCHEMBL29866123 | 0.85 | KMT2A (0.53) | KMT2AMEN1L3MBTL1HPGDTDP1 | |
| SCHEMBL3996930 | 0.85 | KMT2A (0.53) | KMT2AMEN1L3MBTL1HPGDTDP1 | |
| SCHEMBL30240849 | 0.84 | KMT2A (0.56) | KMT2AMEN1L3MBTL1HPGDTDP1 | |
| SCHEMBL3276164 | 0.84 | KMT2A (0.51) | KMT2AMEN1L3MBTL1HPGDTDP1 | |
| SCHEMBL929805 | 0.84 | LOXL2 (0.60) | KMT2AMEN1L3MBTL1NPC1LMNA | |
| SCHEMBL29866166 | 0.84 | KMT2A (0.51) | KMT2AMEN1L3MBTL1HPGDTDP1 | |
| SCHEMBL8828473 | 0.84 | HPGD (0.67) | KMT2AMEN1L3MBTL1HPGDTDP1 | |
| SCHEMBL7044973 | 0.84 | FOLH1 (0.62) | KMT2AMEN1L3MBTL1HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177443-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-10183009-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-9815787-B2 | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof | UNIVERSITY OF TSUKUBA (JP) | 2017-11-14 | — | — | US | disclosed |
| US-9809590-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| EP-1921077-B1 | AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-07-26 | — | — | EP | disclosed |
| EP-2464645-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-15 | — | — | US | disclosed |
| WO-2009062289-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| US-20070197608-A1 | Piperazines as oxytocin agonists | FERRING B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-20070117794-A1 | Methods of treatment using oxytocin receptor agonists | WYETH (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117794-A1 | Methods of treatment using oxytocin receptor agonists | WYETH (US) | 2007-05-24 | — | — | US | disclosed |
| WO-2007050353-A2 | TRICYCLIC COMPOUNDS USEFUL AS OXYTOCIN RECEPTOR AGONISTS | WYETH (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2005023812-A2 | PIPERAZINES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2005-03-17 | — | — | WO | disclosed |
| US-4458081-A | ANTIINFLAMMATORY, ANALGESIC, ANTICOAGULANT, MUSCLE RELAXANT | SYNTEX (U.S.A.) INC. (US) | 1984-07-03 | — | — | US | disclosed |
| US-4454326-A | 5-Aroyl 6-chloro or 6-bromo 1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1,1-di-carboxylates | SYNTEX (U.S.A.) INC. (US) | 1984-06-12 | — | — | US | disclosed |
| US-4347187-A | Process for preparing 5-aroyl 1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acids and novel intermediates therein | SYNTEX (U.S.A.) INC. (US) | 1982-08-31 | — | — | US | disclosed |
| US-4347186-A | Process for preparing 5-aroyl 1,2-dihydro-3-H pyrrolo[1,2-a]pyrrole-1-carboxylic acids and novel intermediates therein | SYNTEX (U.S.A.) INC. (US) | 1982-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | KMT2A 2123/4885MEN1 1384/4885BCL2 4025/4885 |
| US-20070117794-A1 | Methods of treatment using oxytocin receptor agonists | OXTR, AVPR1A, PRLHR | KMT2A 2789/4885MEN1 4369/4885BCL2 2246/4885 |
| US-20220177443-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | IKZF2, IKZF1, IKZF3 | KMT2A 537/4885MEN1 2835/4885BCL2 814/4885 |
| US-10183009-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRPF3 | KMT2A 126/4885MEN1 638/4885BCL2 1666/4885 |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | KMT2A 126/4885MEN1 638/4885BCL2 1666/4885 |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | KMT2A 4586/4885MEN1 4363/4885BCL2 4692/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | KMT2A 4586/4885MEN1 4363/4885BCL2 4692/4885 |
| US-20070197608-A1 | Piperazines as oxytocin agonists | OXTR, OPRL1, AVPR2 | KMT2A 4438/4885MEN1 3461/4885BCL2 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.